nedosiran

Nedosiran (DCR-PHXC) is a GalNAc-dsRNA conjugate designed for RNA interference (RNAi) targeting lactate dehydrogenase (LDH). It serves as a potential therapeutic option for patients with primary hyperoxaluria (PH) and end-stage renal disease (ESRD).

Nedosiran sodium 是一种靶向乳酸脱氢酶 (LDH)的 RNA 干扰剂 (RNAi)。Nedosiran sodium?可用于研究并发终末期肾病 (ESRD)的原发性高草酸尿症 (PH)。